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Abstract
Background: The risk of mortality from pneumonia caused by Streptococcus pneumoniae is increased in
patients with cirrhosis. However, the specific pneumococcal virulence factors and host immune defects
responsible for this finding have not been clearly established. This study used a cirrhotic rat model of
pneumococcal pneumonia to identify defect(s) in innate pulmonary defenses in the cirrhotic host and to
determine the impact of the pneumococcal toxin pneumolysin on these defenses in the setting of severe
cirrhosis.
Results: No cirrhosis-associated defects in mucociliary clearance of pneumococci were found in these
studies, but early intrapulmonary killing of the organisms before the arrival of neutrophils was significantly
impaired. This defect was exacerbated by pneumolysin production in cirrhotic but not in control rats.
Neutrophil-mediated killing of a particularly virulent type 3 pneumococcal strain also was significantly
diminished within the lungs of cirrhotic rats with ascites. Levels of lysozyme and complement component
C3 were both significantly reduced in bronchoalveolar lavage fluid from cirrhotic rats. Finally, complement
deposition was reduced on the surface of pneumococci recovered from the lungs of cirrhotic rats in
comparison to organisms recovered from the lungs of control animals.
Conclusion: Increased mortality from pneumococcal pneumonia in this cirrhotic host is related to
defects in both early pre-neutrophil- and later neutrophil-mediated pulmonary killing of the organisms. The
fact that pneumolysin production impaired pre-neutrophil-mediated pneumococcal killing in cirrhotic but
not control rats suggests that pneumolysin may be particularly detrimental to this defense mechanism in
the severely cirrhotic host. The decrease in neutrophil-mediated killing of pneumococci within the lungs
of the cirrhotic host is related to insufficient deposition of host proteins such as complement C3 on their
surfaces. Pneumolysin likely plays a role in complement consumption within the lungs. Our studies,
however, were unable to determine whether pneumolysin more negatively impacted this defense
mechanism in cirrhotic than in control rats. These findings contribute to our understanding of the defects
in innate pulmonary defenses that lead to increased mortality from pneumococcal pneumonia in the
severely cirrhotic host. They also suggest that pneumolysin may be a particularly potent pneumococcal
virulence factor in the setting of cirrhosis.
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Background
Pneumonia is among the top ten causes of death in the
United States and the most common cause of death due
to infection [1,2]. The Gram positive bacterium Streptococ-
cus pneumoniae is the leading cause of community-
acquired pneumonia [3], and is an increasing concern due
to the emergence of multi-antibiotic resistant strains [4,5].
Certain patient populations are at a particularly increased
risk for pneumococcal infection, including young chil-
dren, the elderly, and patients with immunodeficiencies
or other medical conditions such as cirrhosis [6-9]. Cir-
rhosis is one of the most common causes of acquired
immunodeficiency, and it is well known that mortality
from pneumococcal pneumonia is very high in cirrhotics,
even with appropriate intensive care support and antibi-
otic treatment [10-12]. In one particular multi-center
study, cirrhosis of the liver increased the risk of death
from invasive pneumococcal pneumonia more than any
other condition analyzed [11]. However, the specific
defect(s) in host defense responsible for this increased
morbidity and mortality have not been clearly elucidated.
In order to study the interaction between S. pneumoniae
and innate host defenses in the cirrhotic host, our labora-
tory was the first to develop a cirrhotic rat model of pneu-
mococcal pneumonia [13].
The progression of pneumococcal pneumonia requires
that the organism evade a wide array of innate pulmonary
host defenses. Once S. pneumoniae colonizes the airways,
the mucociliary clearance apparatus, composed of mucus
entrapment and the beating of ciliated epithelial cells lin-
ing the bronchi, prevents pneumococci from moving
down into the lower respiratory tract. If pneumococci
evade this host defense and enter the lungs, they become
deposited on the alveolar lining layer. This thin aqueous
layer covering the surface of the pulmonary epithelium
contains numerous proteins and peptides possessing anti-
bacterial activity. Lysozyme, lactoferrin, β-defensins, and
surfactant within alveolar lining fluid constitute an
important immediate defense against pneumococci prior
to the recruitment of neutrophils [14-16]. Resident alveo-
lar macrophages also phagocytose and kill many types of
organisms that escape mucociliary clearance. However,
previous research has shown that alveolar macrophages
do not efficiently phagocytose and kill highly encapsu-
lated type 3 S. pneumoniae [17-19]. For example, we
showed that only 11% of alveolar macrophages from the
lungs of either cirrhotic or control rats infected with type
3 S. pneumoniae had pneumococci associated with them
[20]. The inability of macrophages to kill this organism
was further confirmed in a murine model of pneumococ-
cal pneumonia in which alveolar macrophage depletion
failed to reduce pneumococcal clearance from the lungs
[21]. Recruited pulmonary neutrophils are an important
host defense against pneumococci. However, for phagocy-
tosis and efficient neutrophil-mediated defense against S.
pneumoniae, the organisms must be opsonized, notably
with fragments of complement component C3 [22,23].
Pneumococci possess multiple virulence factors that facil-
itate evasion of host defenses [24,25]. One such virulence
factor, pneumolysin, is a 53-kDa protein made by all clin-
ical S. pneumoniae isolates. Pneumolysin is a pore-forming
toxin that can be released from lysed or intact pneumo-
cocci during late log phase [26]. Pneumolysin has both
cytotoxic and complement-activating activities [27,28].
The cytotoxic activity affects a wide array of host cells and
contributes to lung damage during the early stages of
pneumococcal pneumonia [29-31]. The complement-
activating activity activates and consumes complement
proteins [32], thus diverting complement away from the
bacterial surface. This activity prevents efficient
opsonophagocytosis and killing by host phagocytes [33].
Our laboratory has previously shown that, like their
human counterparts, cirrhotic rats with ascites are
hypocomplementemic [34] and are more susceptible to
pneumococcal infection. They have increased mortality
compared to control animals following both pulmonary
and intravenous pneumococcal challenges with type 3 S.
pneumoniae [13,34]. In addition, we have shown that the
complement-activating activity of pneumolysin is particu-
larly detrimental to cirrhotic rats following an intravenous
challenge [34]. We therefore hypothesized that the
severely cirrhotic host has increased mortality from pneu-
mococcal pneumonia due to compromised innate
defenses, and pneumolysin may also be especially detri-
mental to the cirrhotic rats during a respiratory tract infec-
tion. To test this hypothesis, we examined several innate
pulmonary anti-pneumococcal defenses and the impact
of pneumolysin in cirrhotic vs. control rats following pul-
monary challenge. Mucociliary clearance, early (pre-neu-
trophil recruitment) and later (neutrophil-mediated)
defenses, and complement deposition on pneumococci
within the rats' lungs were quantified. The effects of pneu-
molysin production by the pneumococci were analyzed
using isogenic mutant pneumococcal strains differing in
their ability to produce pneumolysin.
Results
Mucociliary Clearance Is Not Impaired in Cirrhotic Rats
To determine whether mucociliary clearance is impaired
in cirrhotic rats, the beat frequency of tracheal cilia and
pneumococcal movement from the nasopharynx into the
lungs were quantified. To examine the impact of pneumo-
lysin production on mucociliary clearance, these experi-
ments were performed with isogenic type 3 WU2-derived
pneumolysin-producing (Ply+) and pneumolysin-defi-
cient (Ply-) S. pneumoniae strains. Cirrhotic and control
rats were infected intranasally with 1 × 108 colony formingBMC Microbiology 2007, 7:94 http://www.biomedcentral.com/1471-2180/7/94
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units (cfu) of either the Ply+ or the Ply- strain. The num-
bers of pneumococci reaching the rats' lungs and the beat
frequency of cilia on their tracheal epithelial cells then
were quantified 5 hours post-infection. There were no dif-
ferences between cirrhotic and control rats in the number
of pneumococci recovered from their lungs after infection
with either the Ply+ or Ply- strain (Figure 1). There also
were no differences between the numbers of Ply+ vs. Ply-
pneumococci isolated from the lungs of either group of
rats. Consistent with the equivalent movement of the two
pneumococcal strains into the lungs of cirrhotic and con-
trol rats, the beat frequency of cilia on their tracheal epi-
thelial cells was comparable 5 h after an intranasal
challenge with 1 × 108 cfu of either the Ply+ strain (8.4 ±
0.3 Hz vs. 8.0 ± 0.5 Hz, respectively) or the Ply- strain (9.2
± 1.0 Hz vs. 8.7 ± 0.8 Hz, respectively).
Cirrhosis Impairs Pre-Neutrophil-Mediated Pneumococcal 
Killing within the Lungs
To determine whether early (pre-neutrophil-mediated)
defenses were impaired in the lungs of the cirrhotic host,
in vivo pneumococcal killing assays were conducted
within the rats' lungs. These experiments were performed
with the WU2-derived Ply+ and Ply- mutants to examine
whether pneumolysin production protects S. pneumoniae
from these early pulmonary defenses. The rats were
infected transtracheally with 1 × 106 cfu of Ply+ or Ply- and
then sacrificed exactly 1 hour later, before significant
numbers of neutrophils were detectable in their lungs.
Plate counts of the rats' lung homogenates showed a sig-
nificant decrease (p = 0.035) in pre-neutrophil-mediated
killing of the Ply+ strain in cirrhotic compared to control
rats (Figure 2). By contrast, there was no difference in pre-
neutrophil-mediated killing by the two groups of rats
when the Ply- strain was used. Furthermore, killing of the
Ply+ and Ply- strains was equivalent in the control rats,
whereas killing of the Ply+ strain was significantly lower
(p = 0.038) than that of the Ply- strain in cirrhotic animals.
This suggests that pneumolysin selectively impairs pre-
neutrophil defenses in the cirrhotic host with ascites.
To help elucidate what antibacterial components of pre-
neutrophil defenses were defective within the lungs of the
cirrhotic rats, anti-pneumococcal factors including lys-
ozyme, lactoferrin, and complement component C3 were
quantified in bronchoalveolar lavage fluid. All values
were determined for uninfected cirrhotic and control rats
using enzyme activity or enzyme linked immunosorbent
assays. Mean lysozyme activity was significantly decreased
in the cirrhotic animals compared to controls (1448 U/ml
vs. 1687 U/ml; p = 0.028), whereas levels of lactoferrin
were similar in cirrhotic and control rats (data not
shown). Complement C3 levels in the lavage fluid from
cirrhotic rats also were significantly decreased to less than
half of those in control animals (1185 ng/ml vs. 2443 ng/
ml; p = 0.012).
Pre-neutrophil killing of Ply+ and Ply- S. pneumoniae within  the lungs of cirrhotic and control rats (n = 8–9) measured  exactly 1 hour after a transtracheal challenge with 1 × 106 cfu Figure 2
Pre-neutrophil killing of Ply+ and Ply- S. pneumoniae within 
the lungs of cirrhotic and control rats (n = 8–9) measured 
exactly 1 hour after a transtracheal challenge with 1 × 106 
cfu. The cirrhotic rats killed significantly fewer Ply+ than con-
trol rats (* p = 0.035). Cirrhotic rats also killed significantly 
fewer of the Ply+ than Ply- organisms (** p = 0.038).
0
10
20
30
40
50
60
70
80
90
100
Ply+ Ply-
P
e
r
c
e
n
t
 
o
f
 
P
n
e
u
m
o
c
o
c
c
i
 
K
i
l
l
e
d
Control Rats
Cirrhotic Rats * **
Total number of pneumococci recovered from individual  rats' lungs five hours after an intranasal challenge with 1 ×  108 cfu of pneumolysin sufficient (Ply+) or pneumolysin defi- cient (Ply-) S. pneumoniae Figure 1
Total number of pneumococci recovered from individual 
rats' lungs five hours after an intranasal challenge with 1 × 
108 cfu of pneumolysin sufficient (Ply+) or pneumolysin defi-
cient (Ply-) S. pneumoniae. Horizontal bars represent the 
mean values for each group.
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Cirrhosis Diminishes Neutrophil-Mediated Killing within 
the Lungs
In vivo experiments quantifying neutrophil-mediatedp-
neumococcal killing were conducted by pre-recruiting
neutrophils into the rats' lungs with lipopolysaccharide.
Our laboratory had previously shown that neutrophil
phagocytosis and killing of S. pneumoniae ATCC 6303 are
decreased within the lungs of cirrhotic rats [19,20]. To
determine the impact of pneumolysin on neutrophil-
mediated killing, these experiments were conducted using
the Ply+ and Ply- pneumococcal mutants. Five hours after
recruitment of neutrophils into the lungs there was no
reduction in intrapulmonary killing of either the Ply+ or
Ply- organisms in cirrhotic animals compared to controls
(Figure 3). In addition, the ability of the WU-derived
pneumococci to produce pneumolysin did not affect neu-
trophil-mediated killing in either group of animals.
Because these results differed from our previous findings,
we repeated the assay with S. pneumoniae ATCC 6303. Pul-
monary killing of this strain was significantly decreased (p
= 0.001) in the cirrhotic rats, confirming our previous
findings (Figure 3).
Cirrhosis Diminishes Deposition of Complement C3 on 
Pneumococci
To determine whether reduced pulmonary C3 levels in the
cirrhotic rats corresponded to reduced complement-medi-
ated opsonization of pneumococci within their lungs, we
quantified C3 deposition on pneumococci following
infection. Cirrhotic and control rats were infected tran-
stracheally with 1 × 109 cfu of S. pneumoniae ATCC 6303.
Exactly 15 minutes later, pneumococci recovered from the
lungs of each rat by lavage were treated in vitro with a
FITC-conjugated anti-C3 antibody. Flow cytometry then
was used to quantify C3 deposition on the surface of the
bacteria. The mean percentage of pneumococci with
bound C3 was lower in the cirrhotic rats than in controls
(Figure 4A), but the difference was not statistically signif-
icant (p = 0.075). However, the mean fluorescent intensity
of pneumococci recovered from the lungs was signifi-
cantly decreased (p = 0.04) in the cirrhotic rats (Figure
4B), as was a deposition index calculated by multiplying
the percent of pneumococci positive for C3 by the fluores-
cent intensity (Figure 4C; p = 0.01).
Discussion
Although mucociliary defects previously have not been
linked to cirrhosis, we studied this innate defense because
of its importance in preventing nasal pneumococcal colo-
nization from progressing to a lower respiratory tract
infection. Previous research performed in vitro has indi-
cated that pneumolysin can negatively impact mucocili-
ary clearance [35,36]. To identify potential cirrhosis-
induced deficits in clearance and examine the effects of
pneumolysin on this host defense mechanism in the cir-
rhotic host, the present studies were conducted with
WU2-derived type 3 pneumococcal strains differing only
in their ability to produce pneumolysin. There were no
differences between cirrhotic and control rats in either
pneumococcal movement from the nasopharynx to the
lungs or ciliary beat frequency. Pneumolysin production
also failed to impact pneumococcal movement into the
lungs or mucociliary beating in either group of rats.
Although it is possible that a more pronounced pneumo-
lysin-induced effect would have been found over a longer
post-infection period, pneumolysin does not appear to
preferentially damage this host defense mechanism in the
cirrhotic rats.
The remainder of the studies focused on innate host
defenses taking place within the lungs themselves. These
defenses were analyzed both before and after recruitment
of neutrophils into the rats' lungs by instillation of
lipopolysaccharide. To differentiate these two conditions
they have been designated as pre-neutrophil-mediated
(occurring before neutrophil recruitment) and neu-
trophil-mediated (occurring after recruitment of neu-
trophils into the lungs). Pre-neutrophil-mediated killing
of the Ply+ pneumococcal strain was significantly reduced
in cirrhotic rats compared to controls, whereas killing of
the Ply- strain was equivalent in the two groups of ani-
mals. Moreover, the ability of the organisms to produce
pneumolysin provided a significant protective advantage
against pre-neutrophil-mediated killing in the lungs of cir-
Neutrophil-mediated killing of three S. pneumoniae strains  within the lungs of cirrhotic and control rats (n = 5–6) Figure 3
Neutrophil-mediated killing of three S. pneumoniae strains 
within the lungs of cirrhotic and control rats (n = 5–6). After 
a 5 hour LPS-induced neutrophil recruitment period, rats 
were challenged transtracheally with 1 × 106 of S. pneumoniae 
and killing was quantified exactly 1 hour later. Significantly 
fewer ATCC 6303 organisms were killed by cirrhotic rats 
than by control rats (* p = .001).
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rhotic but not control rats. Taken together, these results
indicate that pre-neutrophil-mediated killing of pneumo-
cocci is diminished in the lungs of our cirrhotic rats, and
that pneumolysin contributes more profoundly to pneu-
mococcal resistance against this innate defense in the set-
ting of cirrhosis. Pneumolysin has been shown to damage
pulmonary cells, disrupt lung integrity, and decrease
phagocyte function [29,32,36-41], all of which are detri-
mental to pulmonary defenses. Damage to the pulmonary
epithelium and endothelium also may be more pro-
nounced in the cirrhotic rats due to reduced macrophage
activity or reduced levels of certain antibacterial factors
even prior to infection.
Although a number of previous studies have quantified
antibacterial components of alveolar lining fluid, such as
lactoferrin, lysozyme, complement, defensins, and sur-
factant [14,15,42-45], to our knowledge they have not
been performed in cirrhotic hosts. Therefore, to help elu-
cidate which types of pulmonary antibacterial compo-
nents are altered in the cirrhotic rats three anti-
pneumococcal factors were quantified in lavage fluid
from uninfected cirrhotic and control rats. Lysozyme
activity was significantly lower in the bronchoalveolar lav-
age fluid of cirrhotic rats compared to their controls. To
our knowledge, this is the first report of a link between
liver damage and decreased lysozyme in lung lavage fluid.
Because lysozyme breaks down peptidoglycan in the
pneumococcal cell wall [42], lowered lysozyme activity
would help explain the diminished pre-neutrophil-medi-
ated killing of pneumococci in the cirrhotic rats.
Our laboratory and others have shown that cirrhotic hosts
are often hypocomplementemic, with decreased levels of
complement component C3 in their serum and ascites
fluid [13,46,47]. The present study demonstrated that C3
levels are also significantly reduced in cirrhotic rats' bron-
choalveolar lavage fluid. This deficiency could negatively
impact innate pulmonary defenses in several ways. First, it
would directly decrease the opsonizing capacity of the
alveolar lining fluid since C3-derived complement com-
ponents are major opsonins for S. pneumoniae [48]. Sec-
ondly, by reducing overall inflammation in the lungs it
would blunt the influx of bactericidal factors from serum.
Finally, reduced pulmonary complement levels would
make the cirrhotic host particularly vulnerable to comple-
ment depletion by the complement-activating activity of
pneumolysin. This would be consistent with previous
work from our laboratory using an intravenous pneumo-
coccal infection model, in which the complement-activat-
ing activity of pneumolysin was especially detrimental for
cirrhotic rats [34]. Unlike control animals, the cirrhotic
animals could not adequately replenish serum comple-
ment that was consumed by pneumolysin during the bac-
teremic infection [46].
Quantification of complement deposition on pneumococci  recovered from the lungs of cirrhotic and control rats 15 min  after infection with 1 × 109 cfu of S. pneumoniae ATCC 6303 Figure 4
Quantification of complement deposition on pneumococci 
recovered from the lungs of cirrhotic and control rats 15 min 
after infection with 1 × 109 cfu of S. pneumoniae ATCC 6303. 
Flow cytometry was used to determine: (A) – percentage of 
pneumococci positive for bound C3; (B) – mean fluorescent 
intensity of pneumococci with bound C3; and (C) – deposi-
tion index calculated by multiplying the percentage of pneu-
mococci positive for C3 by their fluorescent intensity. Both 
the mean fluorescent intensity (*: p = 0.04) and deposition 
index (**: p = 0.01) were significantly lower for organisms 
recovered from the lungs of cirrhotic vs. control rats.
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Because an antibody to rat lactoferrin is not commercially
available, lactoferrin in the rats' lavage fluid was quanti-
fied using a kit designed for human samples. The lactofer-
rin levels determined for the two groups of rats were
equivalent, but this result must be interpreted with cau-
tion because the levels in all of the rats were under 5 ng/
ml. This was most likely due to poor cross-species reactiv-
ity of the antibodies contained in the kit. Because lactofer-
rin has been shown to be directly bactericidal for
pneumococci [49], it will be important for this assay to be
repeated in the future with a rat-specific anti-lactoferrin
antibody when one becomes available.
Pulmonary neutrophil-mediated defenses also were com-
pared in cirrhotic and control rats by pre-recruiting neu-
trophils into the rats' lungs before instillation of the
pneumococci. We used lipopolysaccharide rather than
lipoteichoic acid for this purpose because we previously
demonstrated that lipopolysaccharide has the advantage
of inactivating confounding pre-neutrophil-mediated
anti-pneumococcal factors [50]. This allows the differenti-
ation of neutrophil-mediated killing from non-neu-
trophil-mediated killing. Consistent with our previous
findings [19,20], we observed a reduction in neutrophil-
mediated killing of S. pneumoniae ATCC 6303 in the cir-
rhotic animals. However, there was no difference in kill-
ing between the two groups of animals when they were
challenged with either the Ply+ or Ply- mutants derived
from the WU2 pneumococcal strain. These results may be
explained by inherent differences between the ATCC 6303
and WU2-derived strains. For example, unpublished stud-
ies in our laboratory have shown that even large numbers
of WU2-derived pneumococci injected by the transtra-
cheal route fail to cause mortality in our rats. This indi-
cates that the virulence of pneumococci from this genetic
background is intrinsically inferior to that of ATCC 6303
in our rat model. Even though ATCC 6303 and WU2 are
of the same capsule type, they produce PspA's from com-
pletely different clades. Because PspA has been shown to
decrease complement activation at the pneumococcal sur-
face [51], it is possible that differences in PspA type could
help explain the greater difficulty our hypocomplemen-
temic rats have killing ATCC 6303 within their lungs than
the WU2-derived strains. Given the limited virulence of
the WU2 strains in our rats, it is difficult to use them to
determine whether pneumolysin production impairs pul-
monary neutrophil-mediated killing within the lungs. The
use of isogenic Ply+ and Ply- mutants derived from ATCC
6303 would be ideal for answering this question, but our
attempts to procure these genetically modified strains in
the 6303 background have been unsuccessful to date.
Our laboratory has previously examined the mecha-
nism(s) for decreased neutrophil-mediated killing of S.
pneumoniae  ATCC 6303 in cirrhotic rats. Using in vivo
assays, we demonstrated that adequate numbers of neu-
trophils are recruited into the lungs of cirrhotic rats fol-
lowing a transtracheal infection [52]. However, the
cirrhotic rats' neutrophils are significantly impaired in
their ability to take up the pneumococci when phagocyto-
sis is measured inside the rats' lungs [19,20]. By contrast,
neutrophils isolated from the peripheral blood of cir-
rhotic rats and tested in vitro phagocytosed serum-
opsonized pneumococci as efficiently as neutrophils from
control animals [19]. This indicated that decreased pul-
monary neutrophil phagocytosis in the cirrhotic rats was
not due to inherent defects in the neutrophils themselves
but was more likely due to ineffective opsonization of the
organisms within the cirrhotic rats' lungs. This argument
was strengthened by the present study demonstrating
both significantly decreased levels of complement com-
ponent C3 in the alveolar lining fluid of cirrhotic rats and
decreased complement deposition on the surface of pneu-
mococci recovered from their lungs after a transtracheal
infection. These data provide a potential mechanism to
explain the reduced neutrophil-mediated killing of pneu-
mococci and help explain the impaired clearance of S.
pneumoniae from the lungs of this host with severe cirrho-
sis.
Conclusion
In our rat model of carbon tetrachloride-induced cirrho-
sis, mucociliary clearance appears to be intact, but cir-
rhotic rats have significant impairments in both pre-
neutrophil-mediated and neutrophil-mediated innate
pulmonary defenses against S. pneumoniae. The defect in
the early bactericidal activity of alveolar lining compo-
nents is related, at least in part, to significantly reduced
levels of the antibacterial proteins lysozyme and comple-
ment C3 in the cirrhotic rats. The impairment of neu-
trophil-mediated killing appears to be related to
decreased deposition of complement on the organisms
within the lungs of the cirrhotic rats. The contribution of
pneumolysin production to resistance against pre-neu-
trophil-mediated killing was more pronounced during
infection of cirrhotic vs. control rats. Taken together, these
data indicate numerous defects in innate pulmonary
defenses that help explain the increased susceptibility of
the severely cirrhotic host to pneumococcal pneumonia.
In conjunction with earlier work from our laboratory they
also indicate that consumption of complement by pneu-
molysin may be particularly detrimental to pulmonary
host defenses in a hypocomplementemic cirrhotic host.
Methods
Animals
Outbred 200 gram male Sprague-Dawley rats (Charles
River, Kingston, NY) were housed in solid bottomed cages
with a 12 hour light/dark cycle. They were fed standard rat
chow (Kenwod Feeds, Omaha, NE) ad libitum and tapBMC Microbiology 2007, 7:94 http://www.biomedcentral.com/1471-2180/7/94
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water containing 1.0 mM phenobarbital (Sigma Chemi-
cal, St Louis, MO) for stimulation of the P4502E1 cyto-
chrome system. Cirrhosis was induced by weekly gavage
with the hepatotoxin carbon tetrachloride (CCl4) as
described previously [13]. Briefly, rats under light isoflu-
rane anesthesia (Minrad, Inc., Bethlehem, PA) were gav-
aged weekly for 8–16 weeks with graded doses of CCl4
(Sigma). Two days post-gavage the animals' weight
changes were used to calculate the following week's dose.
All rats used for experimentation were rested from gavage
at least 1 week, had a stable accumulation of abdominal
ascites fluid for at least 2 consecutive weeks, and had cir-
rhotic livers upon dissection. Age-matched control rats
were fed rat chow and water also containing 1.0 mM phe-
nobarbital. They were weighed and gavaged weekly under
anesthesia with equivalent doses of phosphate buffered
saline (PBS) for the same number of weeks. In each of the
experiments, the rats were sacrificed by a 75 mg/kg intra-
peritoneal injection of pentobarbital (Nembutal; Abbott
Laboratories, Chicago, IL) followed by exsanguination.
All experimental procedures were approved by the Institu-
tional Animal Care and Use Subcommittee at the Omaha
Veterans Affairs Medical Center.
Bacterial Strains and Growth Conditions
Three S. pneumoniae strains were used. ATCC 6303 (Amer-
ican Type Culture Collection, Rockville, MD) is a clinical
isolate with a large type 3 capsule that belongs to PspA
clade 5. For determination of the contribution of pneu-
molysin to virulence, certain experiments utilized iso-
genic mutants derived from the WU2 strain of S.
pneumoniae differing only in their ability to produce pneu-
molysin (kindly provided by M. K. Johnson, Tulane Uni-
versity School of Medicine, New Orleans, LA). WU2 is also
a clinical pneumococcal strain that produces a type 3 cap-
sule but, unlike ATCC 6303 belongs to PspA clade 2. WU2
strains are lethal to our rats when given intravenously [34]
but not when infected transtracheally. The Ply+ and Ply-
mutants were created from a spontaneously occurring
rough (nonencapsulated) WU2 isolate (WU2R) as
described previously [53,54]. Briefly, the gene for pneu-
molysin was excised from the chromosome and plasmids
encoding a functional (Ply+) or a disrupted (Ply-) pneu-
molysin gene were transformed into WU2R. Further trans-
formation with DNA from the smooth WU2 parent then
was used to convert both WU2R strains back into the
smooth, encapsulated form.
All S. pneumoniae strains were stored at -80°C in Todd-
Hewitt broth containing 10% glycerol, and grown in
Todd-Hewitt broth at 37°C and 5% CO2. For all experi-
ments, the bacteria were collected by centrifugation,
washed twice with PBS, and diluted to the appropriate
optical density at 540 nm to achieve the desired inoculum
for each experiment. The number of colony-forming units
(cfu's) in the suspension then was determined retrospec-
tively by serial dilution and plating on sheep blood agar
plates (Remel, Lenexa, KS).
Intranasal and Transtracheal Infections
Rats were infected intranasally with S. pneumoniae in a
total of 100 µl of PBS under light isofluorane anesthesia
(Midrad, Inc., Bethlehem, PA) for the mucociliary clear-
ance studies. Following intranasal inoculation, the rats
were held vertically for a few seconds to allow for aspira-
tion of the fluid. Rats were infected transtracheally with S.
pneumoniae under isofluorane anesthesia for the pre-neu-
trophil killing, neutrophil killing, and complement-depo-
sition experiments as described previously [13]. Briefly, a
small incision was made overlying the trachea, the trachea
was made visible by blunt-end dissection, and a 22 gauge
catheter (Becton, Dickinson and Co., Sandy, UT) was
inserted into the trachea. The rat then was placed in a ver-
tical position and the specified inoculum of S. pneumoniae
suspended in 0.3 ml PBS was injected into the catheter.
This was followed by 0.5 ml of air to simulate aspiration.
Analysis of Mucociliary Clearance
Cirrhotic and control rats were infected intranasally with
1 × 108 cfu Ply+ or Ply- WU2 S. pneumoniae grown to late
log phase. Five hours later, the animals were sacrificed and
their lungs were removed en bloc and homogenized in a
final volume of 10 ml ice cold PBS. Pneumococci reaching
the lungs were quantified by standard plate counts of the
serially diluted homogenized lung tissue. Baseline ciliary
beat frequency was quantified on tracheal ring explants
from the same rats using the Sisson-Ammons Analysis
(SAVA) system as described previously [55]. Software by
Ammons Engineering (Mt. Morris, MI) was used for
whole field analysis. The frequency of the beating cilia was
sampled in at least 6 different fields, and each animal's
value was composed of the mean for 6 fields. This data
then was compiled to produce average ciliary beat fre-
quency in Hz for the two different groups of animals.
In vivo Pneumococcal Killing Assays
To measure pulmonary killing of S. pneumoniae by pre-
neutrophil-mediated defenses, cirrhotic and control rats
were infected transtracheally with 1 × 106 cfu of the Ply+
or Ply- WU2-derived S. pneumoniae grown to mid-log
phase. Exactly 1 hour post-infection each rat was sacri-
ficed and its lungs were removed and homogenized as
described above. Plate counts were performed on the
homogenates, and killing of the pneumococci was quan-
tified as the percent decrease in bacterial counts compared
to the mean count obtained from two rats sacrificed
immediately after infection (0 h) using the following for-
mula:BMC Microbiology 2007, 7:94 http://www.biomedcentral.com/1471-2180/7/94
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Percent Killing = (Lung cfu's at 0 h - Lung cfu's at 1 h)/(Lung
cfu's at 0 h) × 100
To quantify killing of S. pneumoniae by pulmonary neu-
trophil-mediated defenses, neutrophils were first pre-
recruited into the rats' lungs by transtracheal instillation
of 20 µg of Escherichia coli O26:B6 lipopolysaccharide
(Sigma, St. Louis, MO) suspended in 0.2 ml of PBS. Five
hours after the instillation of LPS, the rats were infected
transtracheally with 1 × 106 cfu of the ATCC 6303, the
Ply+ WU2, or the Ply- WU2 strains of S. pneumoniae grown
to mid-log phase. Exactly 1 hour post-infection each rat
was sacrificed and its lungs were removed and homoge-
nized. Neutrophil-mediated killing was quantified using
the same formula shown above.
Quantification of Pulmonary Anti-Pneumococcal Factors
Bactericidal factors were quantified in lavage fluid col-
lected from cirrhotic and control rats by in situ bronchoal-
veolar lavage with a single 6 ml aliquot of ice cold PBS.
Cells were removed from the lavage fluid by centrifuga-
tion and the supernatant was filter-sterilized and stored at
-80°C until analyzed. Lysozyme activity in the lavage
samples was quantified using the EnzChek® Lysozyme
Assay Kit (Molecular Probes, Eugene, OR). Lactoferrin was
quantified using Bioxytech® Lactof-EIA for human lactof-
errin (Oxis International, Inc., Portland, OR). Quantifica-
tion of C3 was performed using a commercially available
Rat C3 ELISA kit from Immunology Consultants Labora-
tory, Inc., Newberg, OR.
In vivo Complement Deposition Assay
To quantify C3 deposition on the surface of pneumococci,
cirrhotic and control rats were infected transtracheally
with 1 × 109 cfu of S. pneumoniae ATCC 6303 grown to sta-
tionary phase. Exactly 15 minutes post-infection, each rat
was sacrificed. The lungs were perfused with 30 ml of ice
cold PBS, and then bronchoalveolar lavage was performed
ex vivo. The lungs were washed with 10 ml aliquots of ice
cold Hanks' Balanced Salt Solution without Mg++, Ca++
or phenol red (HBSS, Gibco/Invitrogen, Carlsbad, CA)
that were collected by dependent drainage until a total
volume of 50 ml was recovered. The rat pulmonary cells
were removed from the lavage fluid by centrifugation at
450 × g for 30 minutes. The resulting supernatant was
then centrifuged at 13,776 × g for 10 minutes to collect
pneumococci recovered from the rats' lungs. Any remain-
ing rat cells in the bacterial pellet were lysed twice by the
addition of 10 ml distilled water followed by an equal vol-
ume of double-strength PBS. The final bacterial pellet was
labeled by incubation at 37°C for 30 minutes with a 1:30
dilution of fluorescein-conjugated IgG fraction of goat
anti-rat C3 antibody (Cooper Biomedical, Inc., Malvern,
PA).
Following antibody labeling, the bacteria were washed in
HBSS and fixed in PBS containing 1% formalin for flow
cytometric analysis using a FACSAria flow cytometer (Bec-
ton Dickinson, San Jose, CA). Negative control samples
consisted of the unlabeled bacteria used for rat infection
and bacteria collected from each rat's lungs prior to anti-
body labeling. The positive control consisted of the bacte-
rial suspension used for infection that was opsonized in
vitro  with normal rat serum for 30 minutes and then
labeled with the anti-C3 antibody as described above. On
each day of experimentation, a forward and side scatter
plot of pneumococci grown in culture was used to set the
analysis gate for pneumococci recovered from the rats'
lungs. Histograms of count (number of events) vs. fluores-
cence at 530 nm were used to quantify C3 binding to the
surface of the pneumococci.
Statistical Analyses
All comparisons of values determined for cirrhotic vs.
control rats or Ply+ vs. Ply- were made by Students t test.
Prior to analysis, the data were first tested for normality
and equal variance. If the data were non-parametric, the
Mann-Whitney Rank Sum Test was used. For all tests, a p
value <0.05 was considered significant. Error bars on all
graphs represent standard errors of the means.
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